( MENAFN - EIN Presswire) Vantage Market Research Antibody Drug Conjugates (ADCS) Market Size 2024 | Share by Top Companies, Trends, In-Depth Analysis and Growth Forecast 2030 WASHINGTON, D.C, DISTRICT OF COLUMBIA, UNITED STATES, May 23, 2024 /EINPresswire / -- According to Vantage Market Research the Global Antibody Drug Conjugates (ADCS) Market Size & Share is expected to reach a value of USD 4.75 Billion in 2022.
The Antibody Drug Conjugates (ADCS) Market is projected to showcase a CAGR of 18.80% from 2023 to 2030 and is estimated to be valued at USD 18.84 Billion by 2030.
The Antibody Drug Conjugates (ADCS) Market is witnessing a surge in popularity as a novel therapeutic approach for various diseases. ADCs are engineered molecules that combine the targeting ability of monoclonal antibodies with the potent cell-killing properties of cytotoxic drugs. These drugs work by delivering the cytotoxic payload directly to cancer cells, minimizing damage to healthy tissues – a significant drawback of traditional chemotherapy.
The rising prevalence of cancer, coupled with the limitations of conventional treatments, is driving the demand for ADCs. Additionally, advancements in antibody engineering and linker technology are paving the way for a new generation of highly effective and specific ADCs. Download Sample Reports Here @ Market Dynamics: The ADC market is a complex ecosystem driven by a convergence of scientific advancements, regulatory considerations, and commercial strategi.
